Janus Henderson Group PLC Has $8.34 Million Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Janus Henderson Group PLC lifted its holdings in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 319.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 291,388 shares of the specialty pharmaceutical company's stock after buying an additional 221,903 shares during the period. Janus Henderson Group PLC owned approximately 0.90% of Collegium Pharmaceutical worth $8,341,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in COLL. New Age Alpha Advisors LLC acquired a new position in Collegium Pharmaceutical during the 4th quarter worth $40,000. KBC Group NV lifted its holdings in Collegium Pharmaceutical by 72.5% in the fourth quarter. KBC Group NV now owns 2,336 shares of the specialty pharmaceutical company's stock worth $67,000 after purchasing an additional 982 shares during the period. Nisa Investment Advisors LLC grew its position in Collegium Pharmaceutical by 14.5% in the 4th quarter. Nisa Investment Advisors LLC now owns 2,493 shares of the specialty pharmaceutical company's stock valued at $71,000 after buying an additional 316 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its position in Collegium Pharmaceutical by 10.4% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,838 shares of the specialty pharmaceutical company's stock valued at $196,000 after buying an additional 642 shares in the last quarter. Finally, FORA Capital LLC acquired a new position in Collegium Pharmaceutical during the 4th quarter valued at about $223,000.

Analyst Ratings Changes

COLL has been the subject of a number of research analyst reports. HC Wainwright reaffirmed a "buy" rating and issued a $50.00 price target on shares of Collegium Pharmaceutical in a research note on Monday, March 24th. Piper Sandler reissued a "neutral" rating and set a $37.00 target price (up previously from $36.00) on shares of Collegium Pharmaceutical in a report on Friday, May 9th. Needham & Company LLC restated a "buy" rating and issued a $46.00 target price on shares of Collegium Pharmaceutical in a research report on Wednesday, April 9th. Finally, Wall Street Zen cut Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a research report on Saturday, April 19th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $43.80.

Collegium Pharmaceutical Price Performance

COLL stock traded up $0.04 on Friday, hitting $28.86. 178,265 shares of the company's stock traded hands, compared to its average volume of 427,547. The stock has a market cap of $927.33 million, a price-to-earnings ratio of 12.44 and a beta of 0.63. Collegium Pharmaceutical, Inc. has a 1-year low of $23.23 and a 1-year high of $42.29. The company has a current ratio of 0.97, a quick ratio of 0.88 and a debt-to-equity ratio of 3.43. The stock has a fifty day moving average of $28.11 and a 200-day moving average of $29.74.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The specialty pharmaceutical company reported $1.49 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.50 by ($0.01). Collegium Pharmaceutical had a net margin of 14.78% and a return on equity of 104.67%. The company had revenue of $177.76 million during the quarter, compared to the consensus estimate of $174.96 million. During the same period in the prior year, the company posted $1.45 EPS. Collegium Pharmaceutical's quarterly revenue was up 22.7% on a year-over-year basis. On average, analysts forecast that Collegium Pharmaceutical, Inc. will post 5.62 EPS for the current fiscal year.

Insider Buying and Selling

In related news, EVP Scott Dreyer sold 2,255 shares of the firm's stock in a transaction that occurred on Friday, March 14th. The shares were sold at an average price of $30.00, for a total value of $67,650.00. Following the completion of the transaction, the executive vice president now owns 124,421 shares of the company's stock, valued at approximately $3,732,630. This trade represents a 1.78% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Shirley R. Kuhlmann sold 40,000 shares of Collegium Pharmaceutical stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $28.08, for a total transaction of $1,123,200.00. Following the transaction, the executive vice president now owns 154,204 shares in the company, valued at approximately $4,330,048.32. The trade was a 20.60% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 81,693 shares of company stock worth $2,334,994 in the last three months. 2.51% of the stock is currently owned by insiders.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.